Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.
Eur UrolJul 20, 2026 (epub)
Sian Cooper, Jaymini Patel, Caroline Moore et al.
✦ AI-curated · Sources linked
In 30 seconds
The PACE-B trial, a phase 3 randomized controlled trial, evaluated patient-reported outcomes after 5 years in men with localized prostate cancer treated with stereotactic body radiotherapy (SBRT) versus conventionally fractionated radiotherapy (CRT). At 5 years, urinary incontinence rates were similar: 64% leak-free for SBRT and 69% for CRT, while sexual function declined in both groups.
Key findings
- At 5 years, 64% of SBRT patients were leak-free compared to 69% for CRT.
- 91% of SBRT patients were pad-free versus 90% for CRT at 5 years.
- Intercourse-adequate erections decreased from 35% to 17% for SBRT and from 40% to 20% for CRT.
- Moderate or big bowel problems were reported by 5% of SBRT and 5% of CRT patients at 5 years.
Why it matters
Understanding patient-reported outcomes is crucial for clinicians to assess the long-term effects of prostate cancer treatments on quality of life, particularly regarding urinary and sexual function.